Coronary interventions Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial Fabris E, van’t Hof A, Hamm C, Lapostolle F, Flensted Lassen J, Goodman S, ten Berg J, Bolognese L, Cequier A, Chettibi M, Hammett C, Huber K, Janzon M, Merkely B, Storey R, Zeymer U, Cantor W, Rousseau H, Vicaut E, Montalescot G May 15, 2017 | 10.4244/EIJ-D-16-00965
Coronary interventions Bivalirudin in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: uncertainties almost clarified Huber K, Verheugt F March 20, 2017 | 10.4244/EIJV12I16A315
Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement Capodanno D, Lip G, Windecker S, Huber K, Kirchhof P, Boriani G, Lane D, Gilard M, Collet J-P, Valgimigli M, Byrne R January 22, 2015 | 10.4244/EIJV10I9A174
Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force Gorenek B, Blomström-Lundqvist C, Terradellas J, Camm A, Hindricks G, Huber K, Kirchhof P, Kuck K, Kudaiberdieva G, Lin T, Raviele A, Santini M, Tilz R, Valgimigli M, Vos M, Vrints C, Zeymer U, Kristiansen S January 22, 2015
An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents Katsaros K, Kastl S, Krychtiuk K, Hutter R, Zorn G, Maurer G, Huber K, Wojta J, Christ G, Speidl W June 20, 2014 | 10.4244/EIJV10I2A36
Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care** and Thrombosis of the European Society of Cardiology Hamon M, Pristipino C, Di Mario C, Nolan J, Ludwig J, Tubaro M, Sabaté M, Mauri-Ferre J, Huber K, Niemela K, Haude M, Wijns W, Dudek D, Fajadet J, Kiemeneij F March 22, 2013 | 10.4244/EIJV8I11A192
Time-related impact of distal embolisation on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation De Luca G, Gibson C, Huber K, Dudek D, Cutlip D, Zeymer U, Gyöngyösi M, Bellandi F, Noc M, Arntz H-R, Maioli M, Secco G, Zorman S, Gabriel H, Emre A, Rakowski T, van’t Hof A August 24, 2012 | 10.4244/EIJV8I4A74
Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update Cuisset T, Valgimigli M, Mudra H, Muller O, Wijns W, Huber K May 25, 2010
Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions Cuisset T, Mudra H, Muller O, Vogt P, Angelillo-Scherrer A, Huber K August 20, 2008
Gender-related outcome following percutaneous coronary intervention for ST-elevation myocardial infarction: data from the Austrian acute PCI registry Suessenbacher A, Doerler J, Alber H, Aichinger J, Altenberger J, Benzer W, Christ G, Globits S, Huber K, Karnik R, Norman G, Siostrzonek P, Zenker G, Pachinger O, Weidinger F August 20, 2008
New issue Antiplatelet strategies for complex PCI, are all DES equal at 10-year follow-up? cost-effectiveness of TAVR…find all the answers in the new issue (Intravascular lithotripsy (3.5 mm Shockwave; left), followed by balloon dilatation (4.0 mm NC; right)) December 6, 2019
Trials Book New update! Discover 17 new trials (The Trials book is supported by Biotronik) October 29, 2019
Editorial 2019 – A leap year for valvular heart disease (Course directors PCR London Valves 2019) November 15, 2019